Stockreport

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Organovo Holdings, Inc.  (ONVO) 
NASDAQ:AMEX Investor Relations: organovo.com/about/contact/investor-relations
PDF SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approa [Read more]